The purpose is to determine if StrataCTX® can be used as a steroid sparing agent for the treatment of cutaneous reactions related to, cutaneous T Cell lymphoma (CTCL) and chemotherapy/immunotherapy treatments than the current standard treatment - topical steroids - in people who are receiving treatment for CTCL, or chemotherapy/immunotherapy for solid/hematologic malignancies. Subjects will have CTCL and are being treated with topical steroids, or being treated with chemotherapy/immunotherapy for another condition and have had cutaneous reactions that have warranted initiation of topical steroids.

Topical steroids are the mainstays of treatment for many cutaneous reactions and disorders. Steroids are known to cause many side effects and few effective pharmacologic alternatives exist. Contact dermatitis is observed in 56% of patients with cutaneous T-cell lymphoma (CTCL) being treated with topical mechlorethamine gel. This usually requires chronic treatment with mid-to high-potency steroids. Numerous chemo/immunotherapies are associated with cutaneous reactions including paronychia, hand and foot syndrome, and acneiform rash. Skin toxicity often requires dose reduction of cancer therapies and a variety of skin directed therapies including topical antibiotics and topical steroids. Cutaneous reactions are often the earliest manifestation of acute graft versus host disease. Skin manifestations can be debilitating and treatment usually requires high potency topical steroids. Additional therapies are needed for the treatment of disorders that rely on topical steroids.

Inclusion Criteria:

• Age ≥ 18 years
• Ability to sign informed consent document
• Patient with a diagnosis of CTCL who have contact dermatitis to topical mechlorethamine gel
• Patients with a diagnosis of CTCL who have intractable pruritis
• Patients with a diagnosis of CTCL who rely heavily on topical steroids for symptomatic relief
• Patients on chemo/immunotherapy with drug induced rash

Exclusion Criteria:

• Patients currently undergoing radiotherapy
• Patients currently receiving oral steroids
• Patients who are unable to apply topical medications

Clinical Endpoints/ individual patient data (IPD) will be assessed based on analysis of photos and evaluation of survey data, including scores from Pruritis VAS and Skindex-16 QOL scales. The scores during topical steroid treatment period will be compared to the scores during the StrataCTX® gel treatment period. Safety endpoints will be evaluated based on report of product related adverse events and subsequent study product interruption.